Journal:JBSD:26
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
<hr/> | <hr/> | ||
<b>Molecular Tour</b><br> | <b>Molecular Tour</b><br> | ||
| - | The binding mode of <scene name='Journal:JBSD:26/Cv/2'>erlotinib hydrochloride (ET)</scene>, a targeted anticancer drug, to <scene name='Journal:JBSD:26/Cv/ | + | The binding mode of <scene name='Journal:JBSD:26/Cv/2'>erlotinib hydrochloride (ET)</scene>, a targeted anticancer drug, to <scene name='Journal:JBSD:26/Cv/8'>bovine serum albumin (BSA)</scene> was investigated through 1H NMR, spectroscopic, thermodynamic and molecular modeling methods. Each subdomain is marked with a different colour (<font color='red'><b>red for subdomain IA</b></font>; <span style="color:orange;background-color:black;font-weight:bold;">orange, IB</span>; <span style="color:cyan;background-color:black;font-weight:bold;">cyan, IIA</span>; <span style="color:yellow;background-color:black;font-weight:bold;">yellow, IIB</span>; <span style="color:lime;background-color:black;font-weight:bold;">green, IIIA</span>; <font color='darkmagenta'><b>darkmagenta, IIIB</b></font>). From these methods, the binding parameters, binding site, binding distance, and conformational changes were obtained. Site marker competitive experiments demonstrated that the <scene name='Journal:JBSD:26/Cv/6'>binding site was located in the hydrophobic pocket of site I (subdomain IIA)</scene>. The docking modeling agreed with the results of the fluorescence and displacement experiments. |
</StructureSection> | </StructureSection> | ||
<references/> | <references/> | ||
__NOEDITSECTION__ | __NOEDITSECTION__ | ||
Revision as of 09:57, 3 September 2012
| |||||||||||
- ↑ REF
This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
